Grifols

We are pleased to announce that Dr. Luis Muñoz Becerra from Erlangen (Germany) received the 2024 Grifols Antithrombin Research Award (GATRA) during a virtual ceremony for his project titled I nhibition of serine proteases in tumor associated neutrophil extracellular traps (taNETs) by antithrombin ", whose goal is to explore the potential role of antithrombin to reduce the invasive potential of breast cancer cells.     Dr. Irene Martínez also presented her winner 2022 GATRA research project “Anti-tumor role of antithrombin on glioblastoma multiforme”, whose results are expected to be published soon in an international scientific journal. In the same event, Dr. Bryce A. Kerlin, MD from Ohio (United States of America) was honored with the Albus 2024 Award for his project "Albumin-Dependent Endothelial Cytoprotection" which aims to improve cardiovascular outcomes in hypoalbuminemc-related conditions.    The GATRA and the Albus program, annual international initiatives established in 2015, are meant to foster scientific collaboration and expand knowledge on the therapeutic use of antithrombin and albumin, respectively. #GrifolsScientificAwards

As the year comes to a close, we reflect on our achievements in innovation. From the AdFIrst study, which demonstrated the efficacy of Biotest's fibrinogen concentrate in the treatment of acquired fibrinogen deficiency, to the FDA approvals of our innovative immunoglobulin for primary immunodeficiencies and our fibrin sealant solution for pediatric surgical bleeding. In 2024, we also forged a partnership with BARDA to test an ocular immunoglobulin for treating sulfur mustard-induced eye injuries. Additionally, Gigagen secured a BARDA contract to develop a recombinant polyclonal antibody therapy for botulinum neurotoxins. We’re proud of all that we have accomplished this year and look forward to what we can achieve in 2025! #WeAreInnovation

We want to extend our warmest holiday wishes to our donors, patients, healthcare professionals, and the Grifols Team. ✨ Wishing you a happy and festive holiday season! #WeAreGrifols

We are honored to be the biotech world's most sustainable company. Today we ranked the number one biotechnology company in the S&P Dow Jones Sustainability Indices (DJSI). Ascending to the top position in our fifth year of inclusion strengthens our position as a global leader in sustainability. We remain focused on driving long-term value and making a lasting impact toward a more sustainable, ethical, and resilient future for all stakeholders. Fore more information 👉 http://spr.ly/6040QqXIQ #DJSI #SustainabilityIndice #ESG

We are glad to announce the winner of the second edition of the GRAIT Awards is Michelle M H Tan, currently pursuing a PhD at the Imperial College London. The main goal of her project, entitled “Utilizing T-cell receptor (TCR) sequencing as a prognostic marker to direct intervention in immune thrombocytopenia (ITP)”, is to uncover the mechanisms behind refractoriness to current therapies in some patients with immune thrombocytopenia (ITP)) and ultimately develop more effective, personalized treatments for these patients. Grifols Research Awards in ITP (GRAIT Awards) is an annual European and Middle Eastern award to encourage clinicians and researchers to increase insight into ITP or to improve knowledge of the Spleen Tyrosine Kinase (SYK) inhibition as a mechanism of action. The new GRAIT edition will be announced on the website soon 👉 http://spr.ly/6042QeZtQ #immunology #fostamatinib #ClinicalResearch #GrifolsScientificAwards

Over the years, we have perfected our manufacturing processes to become an industry benchmark for quality, safety, and engineering innovation. We currently have 16 industrial plants in 7 countries, designed and built by Grifols Engineering. This broad international presence allows us to offer development opportunities to our talent. Adrià Matute Blanch started his journey with Grifols as an operator in Parets del Vallès, Spain. After earning his engineering degree, he joined our team in Dublin, Ireland, as an expat. Now, he’s embracing new challenges in Montréal, where we’re building the first plasma-derived medicines manufacturing site in Canada. #GrifolsCanada #WeAreGrifols

Health is a fundamental right of every human being - regardless of race, color, religion, sex, language or any other status. Accessing quality medicine, in a timely and appropriate manner, is fundamental to the full realization of the right to health. At Grifols, we have been working for 115 years to ensure access to plasma-derived medicines to patients across the globe. On Human Rights Day, we reaffirm our commitment to continuously improving the health and well-being of people worldwide. We will keep striving to increase the access to plasma-derived therapies for patients in need. #humanrightsday #WeAreHealthcare

Did you know that the Gri-Fill® dosing system originated after searching for an alternative to autoclave sterilization for solutions? ⚙️ Developed by Victor Grifols i Lucas at the end of the 1980s, the new system combined a polyvinyl chloride (PVC) bag with a filling tube with an integrated filter, making it possible to control the sterility of the solution. The machine also automatically checked the integrity of the filter as a quality control measure. The new system evolved to allow the customized preparation of intravenous solutions in non-standard volumes to meet the individual patient's needs, thus providing better care, while minimizing errors and increasing traceability. Dive into our history of innovation 👉 http://spr.ly/6041QDyaX #PatientSafety #MedicalTechnology #WeAreInnovation

We are honored to sponsor the 10th edition of the #BioRegionReport, a major life sciences and healthcare event bringing together over 800 professionals. #WeAreHealthcare

Congratulations to our first 50 worldwide participants who have just completed the inaugural edition of the Grow Program, an empowering journey for emerging talent at Grifols. 🎓 Over 8 months they have participated in a first-level assessment and engaged in group coaching sessions, as well as receiving mentoring from senior professionals. We are incredibly proud to have such talented individuals on our team and look forward to seeing you excel in your roles and drive our organizational success. #GrifolsTalent